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ABSTRACT 16 
Glioblastoma is the most common and aggressive intrinsic brain tumor in adults. Self-17 
renewing, highly tumorigenic glioma-initiating cells (GIC) have been linked to glioma 18 
invasive properties, immunomodulation and increased angiogenesis leading to resistance to 19 
therapy. TGF-β signaling has been associated with the tumorigenic activity of GIC. TGF-β is 20 
synthesized as a precursor molecule and proteolytically processed to the mature form by 21 
members of the family of the proprotein convertases subtilisin/kexin (PCSK). Here we report 22 
that furin is unique among the PCSK in being highly expressed in human GIC. Furin cleaves 23 
and promotes activation of pro-TGF-β1 and pro-TGF-β2, and TGF-β2 in turn increases furin 24 
levels. Notably, TGF-β2 controls furin activity in an ALK-5-dependent manner involving the 25 
ERK/MAPK pathway. We thus uncover a role of ERK1 in the regulation of furin activity by 26 
supporting a self-sustaining loop for high TGF-β activity in GIC. 27 
28 
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INTRODUCTION 29 
Glioblastoma is the most common malignant primary brain tumor and largely refractory to 30 
current therapies (1). TGF-β has long been attributed a major role in the malignant phenotype 31 
of glioblastoma (2, 3). Cytostatic responses to TGF-β are selectively inhibited in glioblastoma 32 
cells (4) with TGF-β sustaining the migratory and invasive potential as well as suppressing 33 
anti-tumor immune surveillance. Glioma-initiating cells (GIC) have been proposed as the cell 34 
population responsible for tumor initiation and recurrence of gliomas (5) and have been 35 
attributed immunosuppressive properties (6, 7). TGF-β may maintain the stem cell-like 36 
properties and tumorigenic activity of GIC (8-11). TGF-β binding to the TGF-β receptor 37 
complex leads to the activation of both SMAD transcription factors (canonical/SMAD-38 
dependent pathway) (12) and various SMAD-independent pathways including the phospho-39 
inositide 3' kinase (PI3K)/Akt pathway (13), the MEK (MAPK)/ERK, and the p38 and JNK 40 
pathways (14). Persistent activation of the TGF-β pathway in glioblastoma has been described 41 
as an autocrine loop involving TGF-β2, CREB1, SMAD3 and the PI3K/AKT pathway (2). 42 
Processing of pro-TGF-β1 and pro-TGF-β2 in the cytoplasm or in the extracellular matrix in 43 
glioma cells involves pro-protein convertases (PCSK) (15). PCSK are a class of nine enzymes 44 
with a fundamental role in the processing of diverse protein precursors (16). PCSK3, 45 
generally known as furin or paired basic amino acid-cleaving enzyme, is widely expressed 46 
and responsible for most of the processing events in the constitutive secretory pathway. Furin 47 
is located in a variety of cellular compartments including endoplasmatic reticulum, trans-48 
Golgi network and cell surface (17). It is also considered the major endoprotease responsible 49 
for processing TGF-β at its (R/K)-2nX-R↓ site (where n = 0–3 amino acids) (18). TGF-β has 50 
been reported to induce expression of its converting enzyme furin in fibroblasts (19), 51 
epithelial cells (20), and hepatocellular carcinoma cells (21) involving SMAD and MAPK 52 
ERK1/p44 and ERK2/p42. This led us to explore the regulation of furin by these pathways in 53 
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human GIC and specifically the existence and regulation of a potential autocrine TGF-β/furin 54 
loop as a potential therapeutic target for anti-TGF-β treatment in glioblastoma.  55 
 56 
57 
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MATERIAL AND METHODS 58 
Cell culture and reagents 59 
LN-308 and LN-229 kindly provided by N. de Tribolet (Lausanne, Switzerland) were cultured 60 
in DMEM (Gibco/Thermo Fisher, Madison, WI) supplemented with 1% L-glutamine (Gibco) 61 
and 10% FBS (Gibco). The human GIC T-325, T-269, ZH-161, S-24 and ZH-305 (22) were 62 
cultured in phenol red-free Neurobasal medium (NBM) (Gibco) supplemented with 2% B-27 63 
without vitamin A (Gibco) (20 μl/ml), 1% L-glutamine (Gibco) and fibroblast growth factor 64 
and epithelial growth factor (FGF/EGF) (20 ng/ml each) (PeproTech, London, UK). 65 
Treatment of cells was performed in NBM containing 1% L-glutamine and FGF/EGF and the 66 
following reagents: PCSK inhibitor decanoyl-RVKR-CMK (3501, Tocris Bioscience, Bristol, 67 
UK), recombinant human TGF-β2 (R&D Systems, Minneapolis, MN), SD-208 (Scios, 68 
Fremont, CA) and MEK1/2 inhibitor U0126 (9903, Cell Signaling Technology, Danvers, 69 
MA). 70 
Lentivirally-mediated gene silencing of furin was performed as described (23) using a furin 71 
specific shRNA (V3LHS_310002) cloned in a pGIPZ lentiviral vector and the respective 72 
pGIPZ vector carrying a non-targeting control (RHS4349) (Dharmacon, Lafayette, CO). 73 
Transient gene silencing was performed by electroporation (Neon Transfection System, 74 
Invitrogen/ Thermo Fisher) using 100 nM of the following ON-TARGET plus, siRNA 75 
SMART pools from Dharmacon: TGF-β1 (L-012562-00), SMAD2 (L-003561-00), SMAD3 76 
(L-020067-00), SMAD4 (L-003902-00), ERK1 (L-003592-00), ERK2 (L-003555-00) and 77 
non-targeting control (D-001810-10). 78 
Human PBMC were prepared from healthy donor blood and cultured in RPMI (Gibco) 79 
supplemented with 10% fetal bovine serum (FBS) (Gibco), 20 mM L-glutamine, 50 µM β-80 
mercaptoethanol (Sigma, St. Louis, MO), 10 U/ml penicillin (Sigma), 10 µg/ml streptomycin 81 
(Sigma), 10 mM sodium-pyruvate (Sigma), and 1x Minimum essential medium nonessential 82 
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aminoacids (Gibco). Media from GIC seeded at 107 in 10 ml NBM for 72 h were concentrated 83 
2.5-fold prior to the addition to the PBMC. On day 0 PBMC were treated with 3 µg/ml 84 
concavalin A (Sigma), 20 U/ml IL-2 (PeproTech) and GIC conditioned media. At day 3 85 
treatment with IL-2 and exposure to GIC media were repeated, and at day 6 addition of IL-2 86 
was repeated. On day 7 cells were analyzed by flow cytometry. 87 
 88 
Immunoblot analysis 89 
Immunoblot analysis was performed as previously described (23). Primary antibodies were 90 
anti-furin (sc-20801, Santa Cruz Biotechnology, Dallas, TX), anti-β-actin (sc-1616, Santa 91 
Cruz), anti-human LAP/TGF-β1 (AF-246-NA, R&D Systems), anti-TGF-β1 (G1221, 92 
Promega, Madison, WI), anti-TGF-β2 (ab36495, Abcam, Cambridge, UK) and antibodies 93 
from Cell Signaling Technology specific for SMAD1 (9743), phosphorylated SMAD1/5 94 
(Ser463/465) (9516), SMAD2 (3122), phosphorylated SMAD2 (pSMAD2 (Ser465/467)) 95 
(3108), SMAD3 (9513), phosphorylated SMAD3 (pSMAD3 (Ser423/425)) (9520), SMAD4 96 
(9515), p44/42 MAPK (ERK1/2) (9102), phospho-p44/42 MAPK (ERK1/2) (9106), Akt 97 
(9272), phospho-Akt (Ser473) (9271), p38 MAPK (9212), and phospho-p38 MAPK (9211) 98 
Secondary antibodies were HRP-coupled goat anti-rabbit (sc-2004), donkey anti-goat (sc-99 
2033) (Santa Cruz Biotechnology) or sheep anti-mouse antibodies (NA931V, Ge Healthcare 100 
UK limited, Amersham, UK). 101 
 102 
RT-PCR 103 
RT-PCR was performed by using the ΔCT method with ARF1 as a housekeeping gene (see 104 
supplemental table I for primers).  105 
 106 
Furin-specific activity 107 
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Cellular and extracellular furin-specific activity (FSA) was measured as described (24) using 108 
the anti-furin antibody MAB15032 (R&D Systems) as capturing antibody in lysates and 109 
conditioned media of cells seeded at a density of 5x106 cells in 7 ml NBM supplemented with 110 
L-glutamine and FGF/EGF for 48 h. FSA is expressed as the fluorescence intensity 111 
(λexc=380nm, λem=460nm) normalized to protein concentration as determined by Bradford 112 
assay (Bio-Rad, Hercules, CA). FSA was measured in concentrated conditioned media mixed 113 
with the appropriate amount of reaction buffer and analyzed in the same manner as previously 114 
described for the lysates (24). 115 
 116 
Flow cytometry 117 
APC-CD25 (17-0259) and PE-FOXP3 (12-4776) antibodies were from eBioscience (San 118 
Diego, CA), FITC-CD4 (55346) from BD Biosciences (San Jose, CA). FOXP3 119 
fixation/permeabilization kit (eBioscience) was used for FOXP3 staining. Cells were analyzed 120 
with FACS Verse (BD biosciences) and data analyzed with FlowJo software. Fluorescence 121 
Minus One (FMO) controls using fluorochrome-conjugated isotype control antibodies from 122 
BD biosciences (FITC-mouse IgG1, k (555748), APC-mouse IgG1, k (555751) and PE-rat 123 
IgG2A, k (553930)) were used.  124 
  125 
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RESULTS AND DISCUSSION 126 
Seven of the nine PCSK, i.e. PCSK1, PCSK2, PCSK4, PCSK5, PCSK6, PCSK7 and furin, 127 
process their substrate at the consensus recognition sequence (R/K)Xn(R/K)↓ which is also 128 
the recognition site for processing TGF-β. We first investigated mRNA expression levels of 129 
these enzymes in a panel of five human GIC: T-325, T-269, ZH-161, S-24 and ZH-305. 130 
Furin was expressed in all cell lines and one of the most abundant PCSK (Figure 1A). Furin 131 
was detectable intracellularly in cell lysates as a double band of around 100 kDa, 132 
corresponding to the two glycosylated/sialylated forms of mature furin (25) except for T-269 133 
where only the higher molecular mass isoform was detected. In the conditioned media furin 134 
was detectable as a major band with an apparent molecular mass of around 90 kDa (Figure 135 
1B). 136 
To investigate the processing of TGF-β1/2 by furin, lentiviral gene silencing of furin was 137 
performed in T-325, ZH-161 and ZH-305 cells, further referred to as shfurin cells (Figure 1C-138 
E). Furin gene silencing did not affect any other PCSK with the exception of PCSK6 in ZH-139 
305 shfurin cells (data not shown). Decreased protein levels of both cellular and secreted furin 140 
(Figure 1C) and a reduction in cellular and extracellular furin-specific activity (FSA) (Figure 141 
1D) were confirmed in all furin knockdown cell lines. We then analyzed TGF-β1/2 processing 142 
in shfurin cells. For TGF-β1 we used an antibody to the N-terminus of TGF-β1 detecting both 143 
pro-TGF-β1 (55kDa) and the latency associated peptide (LAP) of TGF-β1 (37 kDa) and an 144 
antibody to the C-terminus detecting mature TGF-β1 (12.5 kDa) (see ZH-161/siTGF-β1 as a 145 
control, Figure 1C). For TGF-β2 we used an antibody reacting with the C-terminus of TGF-β2 146 
detecting both pro-TGF-β2 (55 kDa) and mature TGF-β2 (12.5 kDa). Furin gene silencing 147 
resulted in increased levels of pro-TGF-β1 and correspondingly decreased levels of the two 148 
respective processing products LAP/TGF-β1 and mature TGF-β1 in ZH-161 and ZH-305, 149 
with TGF-β1 being not detectable in T-325 (Figure 1C). In T-325 and ZH-305, showing 150 
detectable TGF-β2 protein levels, furin gene silencing increased levels of pro-TGF-β2 and 151 
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decreased levels of mature TGF-β2. The effects of furin gene silencing on pro-TGF-β1/2 152 
processing were similar to those obtained with the pan-proprotein convertase inhibitor 153 
decanoyl-RVKR-CMK (PCSK inhibitor), suggesting that furin is the main PCSK involved in 154 
pro-TGF-β1/2 processing here. Notably, in T-325 and ZH-161 pro-TGF-β processing takes 155 
place to a remarkable extent extracellularly as pro-TGF-β levels increased in shfurin cells and 156 
upon addition of the PCSK inhibitor in the conditioned media, but remained unchanged in the 157 
lysates. In ZH-305, the levels of pro-TGF-β2 increased both in cell lysates and in conditioned 158 
media following furin gene silencing, suggesting that pro-TGF-β2 processing takes place in 159 
part in the intracellular compartment in ZH-305 cells, too (Figure 1C). 160 
To confirm that reduced TGF-β levels affect down-stream signaling activities, we analyzed 161 
the levels of phosphorylated SMAD (pSMAD)2, SMAD3 and SMAD1/5 as readouts for the 162 
activation of canonical TGF-β signal transduction, and of phosphorylated Akt (Ser473) (pAkt 163 
(Ser473)), ERK1/2 (pERK1/2) and p38 (pp38) reflecting non-canonical TGF-β signaling 164 
(Figure 1E). All sh-furin cells showed reduced levels of pSMAD2 and pSMAD3. In ZH-161 165 
and ZH-305 pSMAD1/5 was also reduced, pointing towards a reduction in basal bone 166 
morphogenetic proteins (BMP) signaling upon furin gene silencing, too. Indeed, inhibiting 167 
TGF-β by the TGF-β RI/activin receptor-like kinase (ALK)-5-specific inhibitor SD-208 did 168 
not decrease endogenous pSMAD1,5 levels in GIC, although the increase in pSMAD1,5 by 169 
exogenous TGF-β was blocked (26). The phosphorylation of AKT (Ser467) and p38 was 170 
reduced in T-325 shfurin cells, and ZH-305 shfurin cells showed a reduction in the 171 
phosphorylation of ERK and p38 as well. 172 
TGF-β exerts several immunosuppressive functions, including the promotion of FOXP3+ 173 
regulatory T (Treg) cells. Previous studies have demonstrated that GIC induce Treg 174 
generation in vitro (6). Accordingly, we treated human PBMC with GIC conditioned media 175 
and confirmed the induction of CD4+CD25+FOXP3+ cells: conditioned media of ZH-161 176 
cells increased the fraction of CD4+CD25+FOXP3+ cells from 8.9 to 14.8 ± 0.1%. TGF-β2 177 
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treatment was used as a positive control. To test whether the inhibition of TGF-β processing 178 
affected the ability of GIC to induce Treg, we exposed PBMC to media derived from GIC 179 
treated with the PCSK inhibitor. This led to a decrease in the induction of the 180 
CD4+CD25+FOXP3+ population from 8.9 to 11.1 ± 0.5 % (Figure 1F), indicating that indeed 181 
the inhibition of TGF-β processing in GIC may reduce their immunosuppressive properties. 182 
Similar results were obtained for ZH-305 (data not shown).  183 
Autocrine production of TGF-β may be necessary to maintain GIC stemness and TGF-β 184 
signaling in the tumor microenvironment (27), however, the mechanisms how GIC maintain 185 
high TGF-β activity is not well understood (2). We therefore evaluated the effect of TGF-β2 186 
on furin levels. Indeed, TGF-β2 induced the expression of furin and FSA in all cell lines 187 
except T-269 (Figure 2A-C). To investigate whether the expression of PCSK other than furin 188 
was affected by TGF-β2, we analyzed the mRNA levels of the other six PCSK in ZH-161 189 
(Figure 2D), T-325 and ZH-305 cells (data not shown) cells treated with TGF-β2. Indeed, 190 
none of them was changed, pointing towards a specific effect of TGF-β2 on furin expression. 191 
Concentration and time dependency of furin induction was investigated in ZH-161 cells 192 
(Figure 2E-G). Since we observed an induction on protein levels after 24 h (Figure 2F) and 193 
the maximum effect was achieved with 2.5 ng/ml TGF-β2 (Figure 2G), we selected these 194 
conditions for future experiments. We proceeded to study the signal transduction mechanisms 195 
involved in the regulation of furin by TGF-β2. Exposure of T-325, ZH-161 and ZH-305 to the 196 
ALK-5 inhibitor SD-208 had no effect on constitutive furin protein levels, but abolished TGF-197 
β2-mediated furin induction (Figure 2H). The transient gene silencing of SMAD2, SMAD3 or 198 
SMAD4 did not abrogate the induction of furin expression by TGF-β2, indicating 199 
involvement of SMAD-independent signal transduction (Figure 2I).  200 
Indeed, blocking the MEK1/2 branch of the non-canonical TGF-β pathway by U0126 201 
decreased constitutive furin levels and attenuated the increase in furin levels in response to 202 
TGF-β2. U0126 also decreased constitutive furin levels in T-269 cells which are the TGF-203 
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β2/furin-non-responsive model (Figure 3A). The inhibitory effect of U0126 on the induction 204 
of furin expression by TGF-β2 translated into a reduction in FSA (Figure S1A). Similarly, the 205 
selective gene silencing of ERK1, but not of ERK2, reduced furin basal levels in all cell lines 206 
and attenuated the induction of furin by TGF-β2 (Figure 3B-C). Gene silencing of ERK1, but 207 
not of ERK2, reduced furin on mRNA levels in both basal conditions and upon TGF-β2 208 
treatment (Figure S1B). To address whether the control of furin by ERK1 and TGF-β2 is 209 
associated with a glioma stem cell-like phenotype, we examined the same GIC cultured in 210 
differentiating conditions (Figure S1C) and the long term glioma cell lines, LN-308 and LN-211 
229 (Figure S1D). In both cases ERK1 gene silencing reduced basal furin levels and 212 
attenuated the induction of furin by TGF-2, suggesting that this molecular pattern is shared 213 
between cells with stemness properties and more differentiated tumor cells. The reduction in 214 
furin levels following ERK1 gene silencing was associated with a reduction in pro-TGF-β1/2 215 
processing with increased pro-TGF-β levels and decreased mature TGF-β levels (Figure S1E). 216 
MEK1/2 inhibition did not significantly affect the number of spheres, but the spheres formed 217 
by GIC (T-325, ZH-161 and ZH-305) treated with U0126 were smaller, indicating an 218 
inhibitory effect on cell proliferation as confirmed by reduced MTT metabolism (Figure 3D). 219 
This rather implies a role for the TGF-β-ERK1-furin loop in sustaining the expansion of more 220 
differentiated, i.e. progenitor-like glioma cells, rather than in directly promoting GIC sphere 221 
formation. Targeting ERK1/2 also attenuated the immunosuppressive properties of GIC since 222 
treatment of ZH-161 and ZH-305 cells with U0126 decreased the induction of 223 
CD4+CD25+FOXP3+ cells by conditioned media of ZH-161 (Figure S1F) and ZH-305 (data 224 
not shown). Thus, our findings reveal that the MEK1/2 branch of the non-canonical signaling 225 
pathway, often deregulated in glioma stem cells (28), plays a pivotal role in the control of 226 
furin levels in GIC via ERK1. Altogether, we report that TGF-β induces furin activity in GIC 227 
and we specifically identify the ERK1 pathway as an essential pathway to maintain furin 228 
12 
 
activity. Our findings indicate that the disruption of ERK1 signaling would be a therapeutic 229 
strategy combating TGF-β activity in GIC. 230 
  231 
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FIGURE LEGENDS 325 
FIGURE 1. Furin processes TGF-β in GIC. A. RT-PCR analysis of PCSK1, PCSK2, 326 
PCSK4, PCSK5, PCSK6, PCSK7 and furin. B. Analysis of furin levels by immunoblot in the 327 
lysates and conditioned media. C. Protein levels of furin and precursor forms of TGF-β1/2 328 
were determined in cell lysates and conditioned media of furin-silenced or control cells or 329 
cells treated with 25 μM PCSK inhibitor decanoyl-RVKR-CMK for 48h. Precursor and 330 
mature forms of TGF-β1/2 were determined in the conditioned media of control, furin-331 
depleted and PCSK inhibitor-treated cells. D. Cellular and extracellular FSA was measured in 332 
lysates and conditioned media of control or furin-depleted cells. E. Total SMAD1,2,3 333 
phosphorylated SMAD1,2,3,5, total and phosphorylated AKT, ERK1/2 and p38 levels were 334 
determined in control or furin-depleted cell lysates by immunoblot. In brackets the theoretical 335 
molecular mass is indicated. F. Human PBMC were treated with 2 ng/ml TGF-β2 or 336 
conditioned media from untreated ZH-161 cells or ZH-161 cells treated with 25 µM PCSK 337 
inhibitor decanoyl-RVKR-CMK, in presence of IL-2, for 7 days. Cells were stained for CD4 338 
(FITC), CD25 (APC) and FOXP3 (PE). Scatter plots are gated on CD4+. (P=0.0185 for 339 
PBMC treated with media from PSCK inhibitor-treated versus PSCK inhibitor-untreated ZH-340 
161, unpaired Student’s t-test). All experiments were performed at least twice and data are 341 
mean of triplicates ± SD. 342 
 343 
FIGURE 2. TGF-β2 induces furin in GIC. A-B. Furin expression was analyzed on mRNA 344 
level by RT-PCR (A) and on protein level in cell lysates by immunoblot (B) in GIC treated 345 
with 2.5 ng/ml TGF-β2 for 8h (A) or 24h (B). C. FSA was measured in the cell lysates and in 346 
conditioned media of T-325 and ZH-161 treated with 2.5 ng/ml TGF-β2 for 48 h. D. PCSK1, 347 
PCSK2, PCSK4, PCSK5, PCSK6, PCSK7 and furin mRNA levels in ZH-161 treated with 2.5 348 
ng/ml TGF-β2 for 24 h. E. Furin mRNA levels were measured by RT-PCR in ZH-161 treated 349 
with TGF-β2 for the indicated time points. F. Furin protein levels were analyzed in cell 350 
18 
 
lysates and conditioned media of ZH-161 treated with 2.5 ng/ml TGF-β2 for the indicated 351 
time points by immunoblot. G. ZH-161 were treated with the indicated concentrations of 352 
TGF-β2 for 24 h. Furin protein levels were analyzed in cell lysates by immunoblot. H. Furin 353 
levels were analyzed in the lysates of T-325, ZH-161 and ZH-305 treated with 2.5 ng/ml 354 
TGF-β2, 1 μM SD-208 or the combination of TGF-β2 and SD-208 for 24 h. DMSO was used 355 
as solvent control. I. T-325, ZH-161 or ZH-305 were transfected with siRNA targeting 356 
SMAD2 (left panel), SMAD3 (central panel), SMAD4 (right panel) or non-targeting control 357 
and 24 h later treated with 2.5 ng/ml TGF-β2 for 24 h. Furin was analyzed in the cell lysates 358 
by immunoblot. All experiments were performed at least twice and data are mean of triplicate 359 
± SD. 360 
 361 
FIGURE 3. ERK1 controls furin expression in GIC. A. Furin levels were determined in 362 
GIC pre-incubated with the MEK1/2 inhibitor U0126 (10 μM) for 1 h and then treated with 363 
2.5 ng/ml TGF-β2 for 24 h. DMSO was used as solvent control. B, C. Cells were transfected 364 
with siRNA pools targeting ERK1, ERK2, the combination of ERK1 and ERK2 or non-365 
targeting control. 48 h later T-325, ZH-161, S-24 and ZH-305 were treated with TGF-β2 for 366 
24 h. Furin was analyzed in the cell lysates by immunoblot. D. Sphere formation assay in T-367 
325, ZH-161 and ZH-305 cells treated with 10 µM U0126 or solvent control for 15 days. Data 368 
are absorbance values after MTT addition. All experiments were performed at least twice and 369 
data are mean of triplicate ± SD (* P<0.05, **p<0.01, unpaired Student’s t-test). 370 
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